诺和诺德周三早盘上涨1.9%

Core Viewpoint - Novo Nordisk (NVO) shares rose by 1.9% following the launch of its oral weight loss drug Wegovy in U.S. pharmacies, priced between $149 and $299, with insurance out-of-pocket costs as low as $25. The company faces competition from Eli Lilly, which is awaiting approval for its own oral therapy [1][2]. Group 1 - Novo Nordisk's oral weight loss drug Wegovy is now available in U.S. pharmacies [1][2]. - The cash price for Wegovy ranges from $149 to $299, with potential insurance out-of-pocket costs starting at $25 [1][2]. - Eli Lilly is currently waiting for the approval of its competitive oral therapy [1][2].